Being aware that numerous EGFR inhibitors had been previously discovered as modifiers of ABCB1 and/or ABCG2 [15,19], we explored the potential of furmonertinib to enhance chemosensitivity in multidrug-resistant cancer cells that overexpress ABCB1 or ABCG2. Here, ABCB1 is linked to cancer.